Sentences with word «liraglutide»

The trial was the first of its type to look into the action of liraglutide in the treatment of non-alcoholic steatohepatitis.

Study subjects who received a 3 - milligram (3 - mg) dose of liraglutide lost an average of 8 percent of their body weight (18.7 pounds), compared with just 2.6 percent (6.2 pounds) for subjects receiving a placebo, or «dummy» drug, the investigators reported.

The trial demonstrated that 48 weeks of treatment with liraglutide resulted in 4 out of 10 patients clearing evidence of NASH from their livers.

Subjects who received liraglutide started at a dose of 0.6 mg, which gradually was increased to 3 mg, to minimize side effects, such as nausea.

Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, a new study finds.

«The delay in progression to type 2 diabetes with liraglutide use is likely due to increased weight loss,» Pi - Sunyer said.

Twelve - week results show that liraglutide treatment continues to sustain the weight loss, Pi - Sunyer reported.

Study data also showed that type 2 diabetes developed in three times as many people receiving placebo as those who took liraglutide (14 subjects versus four, respectively).

In general, the researchers found liraglutide 3 mg to have a safety profile that was similar to that found in previous clinical trials of the drug in individuals with Type 2 diabetes treated with lower doses.

The Federal Joint Committee (G - BA) specified metformin plus human insulin as ACT for the new therapeutic indication of insulin degludec / liraglutide when OADs combined with a GLP - 1 receptor agonist do not provide adequate glycaemic control.

For the second arm, among 2,285 individuals with prediabetes, liraglutide went to 1,528 of them and placebo to 757.

Among subjects who had prediabetes at the beginning of the study (arm 2), blood sugar levels reverted to normal in nearly 70 percent of those receiving liraglutide versus 32 percent of people in the placebo group, according to the abstract.

After almost four years of clinical trials, a study on liraglutide has finally concluded.

This class of drugs — which includes Byetta as well as liraglutide (Victoza) are in fact not associated with weight gain despite the increase in insulin levels.

In addition, they were randomly assigned, in a 2 - to - 1 ratio, to a once - daily injection with either 3 mg of liraglutide (2,487 subjects) or placebo (1,244 subjects) for 56 weeks.

On average, individuals treated with liraglutide 3 mg lost 5.4 percent more of their body weight, achieving a total of 8 percent, and nearly 1.7 more inches (4.2 centimeters) around their waist than did those who received placebo, the investigators reported.

In the first arm, which included 1,446 adults who did not have prediabetes, 959 received liraglutide and 487 got the placebo.

The manufacturer dossier therefore provided no relevant data for the assessment, and hence no hint of an added benefit of insulin degludec / liraglutide in combination with OADs can be derived.

These improvements, he said, resulted in a greater reduction in net use of blood pressure drugs and lipid - lowering medications in the liraglutide 3 mg group than in the placebo group.

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP - 1 receptor agonist do not provide adequate glycaemic control.

This is already the second dossier assessment for a therapeutic indication of the fixed combination of insulin degludec / liraglutide in which no hint of an added benefit has been found (see also dossier assessment A15 - 15 from August 2015).

In its literature search on an indirect comparison, the manufacturer identified the randomized controlled trial (RCT) DUAL III, in which insulin degludec / liraglutide was compared with continued ongoing treatment with a GLP - 1 receptor agonist.

Compared with the placebo group, liraglutide - treated subjects also experienced better improvements in blood pressure and levels of all fasting lipids (blood fats), including LDL («bad») cholesterol, HDL («good») cholesterol, triglycerides and total cholesterol, according to Le Roux.

«Insulin degludec plus liraglutide: Again no hint of added benefit in type 2 diabetes: Drug manufacturer presented no relevant data and claimed no added benefit.»

In addition, they were randomly assigned, in a 2 - to - 1 ratio, to a once - daily injection with either 3 mg of liraglutide or placebo for 56 weeks.

Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study.

«Diabetes drug, liraglutide, improves risk factors for heart disease.»

However, it is commonly associated with diabetes, which has prompted researchers to test diabetes medications, such as metformin, rosiglitazone and liraglutide, as potential treatments.

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

For the first time, a large clinical trial showed across - the - board cardiovascular benefit of a diabetes drug — liraglutide — a much - needed outcome for people with type 2 diabetes.

New insulin added dropped from 43.2 % of patients to 28.6 %, meaning that using liraglutide could reduce insulin usage.

In fact, many of these prescriptions — including those containing — lorcaserin, liraglutide, and a combination of phentermine and topiramate — require a Body Mass Index (BMI) higher than 30 or a BMI of 27 and higher along with a weight - related medical condition, like type 2 diabetes or high blood pressure.

In a study of 30 women with PCOS, liraglutide was administered for 12 weeks.